# Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

> **NCT03511196** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 17 (actual)

## Conditions studied

- Prostate Cancer
- Stage IV Prostate Cancer
- Advanced Prostate Cancer
- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** Adaptive Androgen Deprivation Therapy (ADT)
- **DRUG:** Abiraterone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03511196
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-17
- **Primary completion:** 2022-06-22
- **Final completion:** 2026-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03511196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03511196, "Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03511196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*